Bovine adenovirus-3 as a vaccine delivery vehicle

Vaccine

Volumn 33, Issue 4, 2015, Pages 493-499

  Ayalew, Lisanework E ^a,b   Kumar, Pankaj ^a   Gaba, Amit ^a,b   Makadiya, Niraj ^a,b   Tikoo, Suresh K ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

BHV 1 gDt; Bovine adenovirus; Cytokines; Mucosal immunization; Pre existing immunity; Vaccine antigens; Vectored vaccine; Veterinary vaccine

Indexed keywords

ADENOVIRUS VECTOR; ANTIGEN; CYTOKINE; GENOMIC DNA; GLYCOPROTEIN E1; GLYCOPROTEIN E2; GLYCOPROTEIN E4; UNCLASSIFIED DRUG; VACCINE; VIRUS DNA; VIRUS PROTEIN; DRUG CARRIER; LIVE VACCINE; RECOMBINANT VACCINE;

BOVINE ADENOVIRUS; BOVINE ADENOVIRUS 3; COST EFFECTIVENESS ANALYSIS; GENETIC ENGINEERING; MOLECULAR BIOLOGY; NONHUMAN; REVIEW; VACCINATION; VIRAL TROPISM; ANIMAL; BOVINE; CELLULAR IMMUNITY; DRUG DEVELOPMENT; GENE VECTOR; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; MASTADENOVIRUS; PROCEDURES; TRENDS; VETERINARY MEDICINE;

ANIMALS; CATTLE; DRUG CARRIERS; DRUG DISCOVERY; GENETIC VECTORS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MASTADENOVIRUS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VETERINARY MEDICINE;

EID: 84920582140     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.11.055     Document Type: Review

References (96)

1. Davison A.J., Benko M., Harrach B. Genetic content and evolution of adenoviruses. J Gen Virol 2003, 84(11):2895-2908.
2. Berk A. Adenoviridae. The viruses and their replication fields virology 2007, 2355-2398. Lippincott Williams & Wilkins, Philadelphia, PN, 2. D.M. Knipe, P.M. Howley (Eds.).
3. Rowe W.P., Huebner R.J., Gilmore L.K., Parrott R.H., Ward T.G. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 1953, 84(3):570-573.
4. Hilleman M.R., Werner J.H. Recovery of new agent from patients with acute respiratory illness. Proc Soc Exp Biol Med 1954, 85(1):183-188.
5. Enders J.F., Bell J.A., Dingle J.H., Francis T., Hilleman M.R., Huebner R.J., et al. Adenoviruses: group name proposed for new respiratory tract viruses. Science 1956, 124:119-120.
6. Shenk T.E., Adenoviridae: The viruses and their replication. Fundamental virology 2001, 1053-1088. Lippincott Williams, Wilkins, Philadelphia, PA. 4th ed. D.M. Knipe, P.M. Howley, D.E. Griffen (Eds.).
7. Benkö M., Harrach B., Both G.W., Russell W.C., et al. Family adenoviridae. Virus taxonomy. 8th Report of the international committee on taxonomy of viruses 2005, 213-228. Elsevier, New York, NY. C.M. Fauquet, M.A. Mayo, J. Mani-loff, U. Desselberger, L.A. Ball (Eds.).
8. Harrach B., Benkö M., Both G.W., Brown M., Davison A.J., Echavarría M., et al. Family adenoviridae. Virus taxonomy: IXth report of the international committee on taxonomy of viruses 2011, 125-141. Elsevier, New York, NY, USA, 9. A.M.Q. King, E. Lefkowitz, M.J. Adams, E.B. Carstens (Eds.).
9. Chroboczek J., Bieber F., Jacrot B. The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 1992, 186:280-285.
10. Szelechowski M., Fournier A., Richardson J., Eloit M., Klonjkowski B. Functional organization of the major late transcriptional unit of canine adenovirus type 2. J Gen Virol 2009, 90:1215-1223.
11. Kovács G.M., Harrach B., Zakhartchouk A.N., Davison A.J. Complete genome sequence of simian adenovirus 1: an old world monkey adenovirus with two fiber genes. J Gen Virol 2005, 86:1681-1686.
12. Reddy P.S., Idamakanti N., Zakhartchouk A.N., Baxi M.K., Lee J.B., Pyne C., et al. Nucleotide sequence, genome organization, and transcription map of bovine adenovirus type 3. J Virol 1998, 72(2):1394-1402.
13. Nagy M., Nagy E., Tuboly T. The complete nucleotide sequence of porcine adenovirus sero-type 5. J Gen Virol 2001, 82:525-529.
14. Reddy P.S., Idamakanti N., Song J.Y., Lee J.B., Hyun B.H., Park J.H., et al. Nucleotide sequence and transcription map of porcine adenovirus type 3. Virology 1998, 251(2):414-426.
15. Russell W.C. Update on adenovirus and its vectors. J Gen Virol 2000, 81:2573-2604.
16. Yang T.C., Dayball K., Wan Y.H., Bramson J. Detailed analysis of the CD8+ T-cell response following adenovirus vaccination. J Virol 2003, 77(24):13407-13411.
17. Yang T.C., Millar J.B., Grinshtein N., Bassett J., Finn J., Bramson J.L. T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev Vaccines 2007, 6(3):347-356.
18. Prevec L., Campbell J.B., Christie B.S., Belbeck L., Graham F.L. A recombinant human adenovirus vaccine against rabies. J Infect Dis 1990, 161(1):27-30.
19. Torres J.M., Alonso C., Ortega A., Mittal S., Graham F., Enjuanes L. Tropism of human adenovirus type 5-based vectors in swine and their ability to protect against transmissible gastroenteritis coronavirus. J Virol 1996, 70:3770-3780.
20. Gogev S., Vanderheijden N., Lemaire M., Schynts F., D'Offay J., Deprez I., et al. Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD. Vaccine 2002, 20:1451-1465.
21. Montiel N.A., Smoliga G., Arzt J. Time-dependent biodistribution and transgene expression of a recombinant human adenovirus serotype 5-luciferase vector as a surrogate for rAd5-FMDV vaccines in cattle. Vet Immunol Immunopathol 2013, 151(1-2):37-48.
22. Toro H., van Ginkel F.W., Tang D.C., Schemera B., Rodning S., Newton J. Avian influenza vaccination in chickens and pigs with replication-competent adenovirus-free human recombinant adenovirus 5. Avian Dis 2010, 54(1):224-231.
23. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006, 80:1959-1964.
24. Tordo N., Foumier A., Jallet C., Szelechowski M., Klonjkowski B., Eloit M. Canine adenovirus based rabies vaccines. Dev Biol 2008, 131:467-476.
25. Hammond J.M., Jansen E.S., Morrissy C.J., van der Heide B., Goff W.V., Williamson M.M., et al. Vaccination of pigs with a recombinant porcine adenovirus expressing the gD gene from pseudorabies virus. Vaccine 2001, 19(27):3752-3758.
26. Tuboly T., Nagy E. Construction and characterization of recombinant porcine adenovirus serotype 5 expressing the transmissible gastroenteritis virus spike gene. J Gen Virol 2001, 82:183-190.
27. Zakhartchouk A.N., Pyne C., Mutwiri G.K., Papp Z., Baca-Estrada M.E., Griebel P., et al. Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1. J Gen Virol 1999, 80(5):1263-1269.
28. Kumar P., Ayalew L.E., Godson D.L., Gaba A., Babiuk L.A., Tikoo S.K. Mucosal immunization of calves with recombinant bovine adenovirus-3 co-expressing truncated form of bovine herpesvirus-1 gD and bovine IL-6. Vaccine 2014, 32(26):3300-3306.
29. Deng L., Sharif S., Nagy E. Oral inoculation of chickens with a candidate fowl adenovirus 9 vector. Clin Vaccine Immunol 2013, 20(8):1189-1196.
30. Shinagawa M., Iida Y., Matsuda A., Tsukiyama T., Sato G. Phylogenetic relationships between adenoviruses as inferred from nucleotide sequences of inverted terminal repeats. Gene 1987, 55:85-93.
31. Xing L., Zhang L.N., Van Kessel J., Tikoo S.K. Identification of cis-acting sequences required for selective packaging of bovine adenovirus type 3 DNA. J Gen Virol 2003, 84:2947-2956.
32. Xing L., Tikoo S.K. Bovine adenovirus-3 E1A coding region contain cis-acting DNA packaging motifs. Virus Res 2007, 130(1-2):315-320.
33. Xing L., Tikoo S.K. E1A promoter of bovine adenovirus type 3. J Gen Virol 2006, 87(12):3539-3544.
34. Baxi M.K., Babiuk L.A., Mehtali M., Tikoo S.K. Transcription map and expression of bovine herpesvirus-1 glycoprotein D in early region 4 of bovine adenovirus-3. Virology 1999, 261:143-152.
35. Reddy P.S., Chen Y., Idamakanti N., Pyne C., Babiuk L.A., Tikoo S.K. Characterization of early region 1 and pIX of bovine adenovirus-3. Virology 1999, 253(2):299-308.
36. Idamakanti N., Reddy P.S., Babiuk L.A., Tikoo S.K. Transcription mapping and characterization of 284R and 121R proteins produced from early region 3 of bovine adenovirus type 3. Virology 1999, 256:351-359.
37. Zheng B.J., Graham F.L., Prevec L. Transcription units of E1a, E1b and pIX regions of bovine adenovirus type 3. J Gen Virol 1999, 80:1735-1742.
38. Kulshreshtha V., Babiuk L.A., Tikoo S.K. Role of bovine adenovirus-3 33K protein in viral replication. Virology 2004, 323:59-69.
39. Kulshreshtha V., Tikoo S.K. Interaction of bovine adenovirus-3 33K protein with other viral proteins. Virology 2008, 381(1):29-35.
40. Ayalew L.E., Gaba A., Kumar P., Tikoo S.K. Conserved regions of bovine adenovirus-3 pVIII contain functional domains involved in nuclear localization and packaging in mature infectious virion. J Gen Virol 2014, 95:1743-1754.
41. Makadiya N. Functional characterization of 100K protein of bovine adenovirus type 3 2013, University of Saskatchewan, Saskatoon, (Ph.D. thesis).
42. Paterson C.P., Ayalew L.E., Tikoo S.K. Mapping of nuclear import signal and importinα3 binding regions of 52K protein of bovine adenovirus-3. Virology 2012, 432:63-72.
43. Ruigrok R.W., Barge A., Mittal S.K., Jacrot B. The fibre of bovine adenovirus type 3 is very long but bent. J Gen Virol 1994, 75:2069-2073.
44. Wu Q., Tikoo S.K. Altered tropism of recombinant bovine adenovirus type-3 expressing chimeric fiber. Virus Res 2004, 99(1):9-15.
45. Mittal S.K., Prevec L., Graham F.L., Babiuk L.A. Development of a bovine adenovirus type 3-based expression vector. J Gen Virol 1995, 76:93-102.
46. Zakhartchouk A.N., Reddy P.S., Baxi M., Baca-Estrada M.E., Mehtali M., Babiuk L.A., et al. Construction and characterization of E3-deleted bovine adenovirus type 3 expressing full-length and truncated form of bovine herpesvirus type 1 glycoprotein gD. Virology 1998, 250:220-229.
47. van Olphen A.L., Mittal S.K. Generation of infectious genome of bovine adenovirus type 3 by homologous recombination in bacteria. J Virol Methods 1999, 77(2):125-129.
48. Chartier C., Degryse E., Gantzer M., Dieterle A., Pavirani A., Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996, 70:4805-4810.
49. Rasmussen U.B., Benchaibi M., Meyer V., Schlesinger Y., Schughart K. Novel human gene transfer vectors: evaluation of wild-type and recombinant animal adenoviruses in human-derived cells. Hum Gene Ther 1999, 10:2587-2599.
50. Du E., Tikoo S.K. Efficient replication and generation of recombinant bovine adenovirus-3 in nonbovine cotton rat lung cells expressing I-SceI endonuclease. J Gene Med 2010, 12(10):840-847.
51. Zhou Y., Reddy P.S., Babiuk L.A., Tikoo S.K. Bovine adenovirus type 3 E1B (small) protein is essential for growth in bovine fibroblast cells. Virology 2001, 288(2):264-274.
52. Reddy P.S., Idamakanti N., Chen Y., Whale T., Babiuk L.A., Mehtali M., et al. Replication-defective bovine adenovirus type 3 as an expression vector. J Virol 1999, 73:9137-9144.
53. van Olphen A.L., Tikoo S.K., Mittal S.K. Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. Virology 2002, 295:108-118.
54. Van Olphen A.L., Mittal S.K. Development and characterization of bovine X human hybid cell lines that efficiently support the replication of both wild-type bovine and human adenoviruses and those with E1 deleted. J Virol 2002, 76:5882-5892.
55. Reddy P.S., Idamakanti N., Zakhartchouk L.N., Babiuk L.A., Mehtali M., Tikoo S.K. Optimization of bovine coronavirus hemagglutinin-esterase glycoprotein expression in E3 deleted bovine adenovirus-3. Virus Res 2000, 70(1-2):65-73.
56. Zhang L., Gomis S., Tikoo S.K. Evaluation of promoters for foreign gene expression in E3 region of bovine adenovirus type 3. Virus Res 2005, 110:169-176.
57. Baxi M.K., Deregt D., Robertson J., Babiuk L.A., Schlapp T., Tikoo S.K. Recombinant bovine adenovirus type 3 expressing bovine viral diarrhea virus glycoprotein E2 induces an immune response in cotton rats. Virology 2000, 278:234-243.
58. Baxi M.K., Robertson J., Babiuk L.A., Tikoo S.K. Mutational analysis of early region 4 of bovine adenovirus type 3. Virology 2001, 290(1):153-163.
59. Van Drunen Little-van den Hurk S., Parker M.D., Massie B., van den Hurk J.V., Harland R., Babiuk L.A., Zamb T.J. Protection of cattle from BHV-1 infection by immunization with recombinant glycoprotein gIV. Vaccine 1993, 11:25-35.
60. Ridpath J.F. Immunology of BVDV vaccines. Biologicals 2013, 41:14-19.
61. Deregt D., Giffor G.A., Ijak M.K., Watts T.C., Gilchrist J.E., Haines D.M., et al. Monoclonal antibodies to bovine coronavirus glycoproteins E2 and E3: demonstration of in vivo virus-neutralizing activity. J Gen Virol 1989, 70:993-998.
62. Mittal S.K., Middleton D.M., Tikoo S.K., Babiuk L.A. Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus). Virology 1995, 213(1):131-139.
63. Ghirotti M., Semproni G., De Meneghi D., Mungaba F.N., Nannini D., Calzetta G., et al. Sero-prevalences of selected cattle diseases in the Kafue flats of Zambia. Vet Res Commun 1991, 15:25-36.
64. Lehmkuhl H.D., Smith M.H., Gough P.M. Neutralizing antibodies to bovine adenovirus serotype 3 in healthy cattle and cattle with respiratory tract disease. Am J Vet Res 1979, 40:580-583.
65. Reddy P.S., Idamakanti N., Pyne C., Zakhartchouk A.N., Godson D.L., Papp Z., et al. The immunogenicity and efficacy of replication-defective and replication-competent bovine adenovirus-3 expressing bovine herpesvirus-1 glycoprotein gD in cattle. Vet Immunol Immunopathol 2000, 76(3-4):257-268.
66. Roshtkhari F., Mohammadi G., Mayameei A. Serological evaluation of relationship between viral pathogens (BHV-1, BVDV, BRSV, PI-3V, and Adeno3) and dairy calf pneumonia by indirect ELISA. Trop Anim Health Prod 2012, 44:1105-1110.
67. Mittal S.K., Tikoo S.K., Van Donkersgoed J., Beskorwayne T., Godson D.L., Babiuk L.A. Experimental inoculation of heifers with bovine adenovirus type 3. Can J Vet Res 1999, 63(2):153-156.
68. Moraes M.P., Mayr G.A., Mason P.W., Grubman M.J. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 2002, 20(11-12):1631-1639.
69. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005, 79(10):6516-6522.
70. Gao W., Soloff A.C., Lu X., Montecalvo A., Nguyen D.C., Matsuoka Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-basede immunization. J Virol 2006, 80:1959-1964.
71. Toro H., Tang D.C., Suarez D.L., Sylte M.J., Pfeiffer J., Van Kampen K.R. Protective avian influenza in-ovo vaccination with non-replicating human adenovirus vector. Vaccine 2007, 25(15):2886-2891.
72. Robert B., Kumar P., Babiuk L.A., Tikoo S.K. Recombinant bovine adenovirus -3 co-expressing bovine respiratory syncytial virus glycoprotein G and truncated glycoprotein gD of bovine herpesvirus-1 induce immune responses in cotton rats. Mol Biotechnol 2014, 10.1007/s12033-014-9801-x.
73. Ramsay A.J., Kohonsen-Corish M. Interleukin-5 expressed by a recombinant virus vector enhances specific mucosal IgA responses in vivo. Eur J Immunol 1993, 23:3141-3145.
74. Ramsay A.J., Husband A.J., Ramshaw I.A., Bao S., Matthaei K.I., Koehler G., Kop M. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994, 264:561-563.
75. Braciak T.A., Gallichan W.S., Graham F.L., Richards C.D., Ramsay A.J., Rosenthal K.L., et al. Recombinant adenovirus vectors expressing interleukin-5 and -6 specifically enhance mucosal immunoglobulin A responses in the lung. Immunology 2000, 101(3):388-396.
76. Lietz R., Bayer W., Ontikatze T., Johrden L., Tenbusch M., Storcksdieck Genannt Bonsmann M., et al. Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection. J Virol 2012, 86(3):1706-1716.
77. Bayer W., Lietz R., Ontikatze T., Johrden L., Tenbusch M., Nabi G., et al. Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology 2011, 8:75-85.
78. Chinsangaram J., Moraes M.P., Koster M., Grubman M.J. Novel viral disease control strategy: adenovirus expressing alpha interferon rapidly protects swine from foot-and-mouth disease. J Virol 2003, 77:1621-1625.
79. Wu Q., Brum M.C., Caron L., Koster M., Grubman M.J. Adenovirus-mediated type I interferon expression delays and reduces disease signs in cattle challenged with foot-and-mouth disease virus. J Interferon Cytokine Res 2003, 23(7):359-368.
80. Ragoo C., Habermehl M., Babiuk L.A., Griebel P. The in vivo effects of recombinant bovine herpesvirus-1b expressing bovine interferon-gamma. J Gen Virol 2000, 81:2665-2673.
81. Zhang C., Wang B., Wang M. GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease. Virol J 2011, 8:7-16.
82. Su B., Wang J., Wang X., Jin H., Zhao G., Ding Z., et al. The effects of IL-6 and TNF-alpha as molecular adjuvants on immune responses to FMDV and maturation of dendritic cells by DNA vaccination. Vaccine 2008, 26(40):5111-5122.
83. Cerretti D.P., McKereghan K., Larsen A., Cosman D., Gillis S., Baker P.E. Cloning, sequence, and expression of bovine interferon-gamma. J Immunol 1986, 136(12):4561-4564.
84. Baker P.E. Bovine interleukin 2: cloning, high level expression, and purification. Vet Immunol Immunopathol 1987, 17(1-4):193-209.
85. Droogmans L., Cludts I., Cleuter Y., Kettmann R., Burny A. Nucleotide sequence of bovine interleukin-6 cDNA. DNA Seq 1992, 2:411-413.
86. Zakhartchouk A., Connors W., van Kessel A., Tikoo S.K. Bovine adenovirus type 3 containing heterologous protein in the C-terminus of minor capsid protein IX. Virology 2004, 320(2):291-300.
87. Azizi A., Kumar A., Diaz-Mitoma F., Mestecky J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog 2010, 6:1-7.
88. Clark M.A., Jepson M.A., Hirst B.H. Exploiting M cells for drug and vaccine delivery. Adv Drug Delivery Rev 2001, 50:81-106.
89. Higgins L.M., Lambkin I., Donnely G., Byrne D., Wilson C., Dee J., et al. In-vivo phage display to identify M cell-targeting ligands. Pharm Res 2004, 21:695-705.
90. Bangari D.S., Shukla S., Mittal S.K. Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun 2005, 327(3):960-966.
91. Darbyshire J.H. Oncogenicity of bovine adenovirus-3 in hamsters. Nature 1966, 211:102.
92. Zalmanzon E.S., Vinkele R.A., Grigor'eva L.V., Turetskaia R.L. Vopr Onkol 1981, 27:61-68.
93. Robert-Gurroff M. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 2007, 18(6):546-556.
94. Gomez-Roman V.R., Grimes G.J., Potti G.K., Peng B., Demberg T., Gravlin L., et al. Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. Vaccine 2006, 24:5064-5072.
95. Gurwith M., Lock M., Taylor E.M., Ishioka G., Alexander J., Mayall T., et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomized, double blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013, 13:238-250.
96. Lichtenstein D.L., Wold W.S.M. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety and transmission. Cancer Gene Ther 2004, 11:819-829.